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A b s t r a c t
Background: We believe that there is a physiological link between intracellular iron status (assessed by soluble transferrin 
receptor [sTfR]) and efficiency of energy production/consumption (assessed by lactate, a product of anaerobic cell metabolism), 
which may further impact the outcome of patients with acute heart failure (AHF).
Aim: To examine if elevated levels of lactate (> 2 mmol/L) accompanied by unmet cellular iron requirements (defined as 
sTfR > 1.59 mg/L) identify AHF patients with an unfavourable outcome.
Methods: The study is a single-centre, retrospective analysis of AHF patients in whom lactate and iron status were assessed 
on admission. The endpoint of the study was one-year mortality.
Results: The study population consisted of 89 patients at a mean age of 65 ± 13 years. Mean systolic blood pressure and 
creatinine level were 135 ± 36 mmHg and 1.3 ± 0.6 mg/dL, respectively, and median [25th–75th quartiles] lactate level on 
admission was 2.0 [1.6–2.6] mmol/L. In 17 (19%) patients, both lactate and sTfR were below the cut-off values (group 1). In 
38 (43%) individuals one of the markers was elevated (group 2) and in the remaining 34 (38%) patients both markers were 
above the predefined cut-off values (group 3). There was no difference in clinical and laboratory characteristics between 
the groups. During one-year follow-up 23 (26%) patients died. Mortality risk in group 3 was higher compared to the rest 
of the population (hazard ratio 5.6, 95% confidence interval 2.2–14, p = 0.0003), even after adjustments for well-defined 
prognostic factors.
Conclusions: Patients with unmet iron cell requirements and hyperlactataemia on admission have significantly higher mortality 
risk compared to individuals without those pathologies.
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INTRODUCTION
Acute heart failure (AHF) is a syndrome with complex patho-
physiology and it should not be simplified only to congestion 
and inadequate cardiac output [1, 2]. We believe that during 
every AHF episode the patient is exposed to metabolic stress 
driven by neurohormonal and adrenergic activation, which 
may lead to organ dysfunction [3–8]. Patients unable to cope 
with the stress may have a worse outcome.
In the traditional approach, lactate is believed to be an 
end-product of anaerobic cell metabolism, which occurs 
during oxidative stress [9, 10]. This marker is continuously 
produced and cleared to maintain its physiological con-
centration [11]. Compromised adaptation reflected by the 
inability to maintain the balance between lactate production 
and elimination results in its systemic accumulation [10, 11]. 
Inadequate peripheral perfusion, low cardiac output, activa-
tion of sympathetic drive, vasoconstriction, organ dysfunction, 
as well as anaemia and iron deficiency can all conspire to 
promote energetic/metabolic oppression in AHF, which may 
further manifest as hyperlactataemia [10–12]. Only recently 
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has the prognostic significance of lactate acid in heart failure 
(HF)  been shown [8, 13, 14].
Iron is a vital cofactor and catalyst of enzymes that regu-
late cell energy production [15]. It is also a key micronutri-
ent crucial for erythropoiesis, oxygen transport, and tissue 
oxygenation [15]. Thus, iron deficiency may lead to the 
dysregulation of several mechanisms that buffer cell energetics 
and therefore promote the anaerobic (less efficient) pathway 
of energy supply. There are several biomarkers reflecting dif-
ferent iron statuses, such as serum iron, transferrin saturation 
(TSAT), and serum ferritin. Unfortunately, those variables are 
affected by many external factors and therefore seem to be 
unreliable in the AHF setting [15]. Soluble transferrin receptor 
(sTfR) is a transmembrane cell receptor that is shed from cells 
to incorporate iron into the cells. Therefore, elevated sTfR is 
a marker reflecting unmet intracellular iron requirements.
There should be a strong pathophysiological link between 
cellular iron status and the efficiency of energy production 
and, consequently, the ability to adapt to the stress related to 
an AHF event. Although there are reasons to believe that both 
iron deficiency and elevated lactate (separately) have prognos-
tic significance in HF, there are no data on their coexistence 
and its clinical consequences in AHF [8, 16].
We aimed to examine if elevated lactate levels 
(> 2 mmol/L) accompanied by unmet cellular iron require-
ments (defined as sTfR elevation > 1.59 mg/L) on admission 
identify patients with an unfavourable outcome.
METHODS
The study population consisted of patients hospitalised at the 
Centre for Heart Diseases, 4th Military Hospital, Wroclaw, 
Poland, between 2010 and 2012 [16] with primary diagnosis 
of AHF, in whom sTfR and lactate levels could be assessed. Pa-
tients with known liver disease, on dialysis, with any treatment 
for anaemia as well as those with clinical diagnosis of acute 
coronary syndrome or cardiogenic shock were excluded. After 
enrolment, information on demographics, clinical history, 
comorbidities, previous therapies, and physical examination 
findings was recorded. Lactate levels were assessed on admis-
sion as part of a standard capillary blood gas test.
Laboratory measurements
On admission, the following laboratory measurements were 
taken using standard methods (blood samples were drawn at 
the Emergency Department or within the first hour of hospi-
talisation as part of standard AHF patient care):
 — capillary blood for oxygen saturation (%), carbon dioxide 
concentration (mmHg), pH, bicarbonate (mmol/L), and 
lactate (mmol/L); direct method, ABL 800 Flex analyser, 
(Radiometer, Copenhagen, Denmark);
 — haematology: haemoglobin (g/dL; conversion factor to SI 
units: 10 [g/L]), white blood cell count (G/L; conversion 
factor to SI units: 1), platelet count (G/L; conversion fac-
tor to SI units: 1);
 — serum electrolytes: sodium (Na+, mmol/L);
 — renal test: creatinine (mg/dL; conversion factor to SI 
units: 88.4 [µmol/L]); estimated glomerular filtration rate 
(eGFR) calculated by the Modification of Diet in Renal 
Disease (MDRD) formula: eGFR = 175 × serum Cr–1.154 × 
× age–0.203 × 1.212 (if patient is black) × 0.742 (if female); 
serum creatinine in mg/dL was used for this formula;
 — liver function tests: aspartate aminotransferase (AST, 
IU/L), alanine aminotransferase (IU/L), bilirubin (mg/dL; 
conversion factor to SI units: 17.1 [µmol/L]);
 — plasma N-terminal pro–B-type natriuretic peptide 
(NT-proBNP); immunoenzymatic assay (Siemens, Mar-
burg, Germany).
The following measurements of iron status were per-
formed:
 — serum ferritin (mg/L) measured using an immunoassay 
based on electrochemiluminescence with the Elecsys 
2010 System (Roche Diagnostics GmbH, Mannheim, 
Germany);
 — serum iron (mg/dL) and total iron-binding capacity (TIBC, 
mg/dL) assessed using a substrate method with Feren S 
(Thermo Fisher Scientific, Waltham, MA, USA);
 — serum sTfR (mg/L) measured from plasma frozen at 
−70oC using immunonephelometry (Siemens Healthcare 
Diagnostics, Inc., Deerfield, IL, USA);
 — serum hepcidin (ng/mL) was measured from plasma 
frozen at −70°C using a commercially available en-
zyme-linked immunosorbent assay (ELISA) (BACHEM) 
(Cat. No. S-1337 detecting human hepcidin-25). The 
ELISA method was validated with liquid chromatography 
mass spectrometry, the gold standard for hepcidin as-
sessment.
Transferrin saturation was calculated as the ratio of serum 
iron (mg/dL) and TIBC (mg/dL) multiplied by 100 and ex-
pressed as a percentage. In accordance with previous reports, 
iron deficiency was defined as serum ferritin < 100 µg/L or 
serum ferritin 100–299 µg/L and TSAT < 20%.
During hospitalisation every patient underwent standard 
clinical evaluation and received guideline-recommended 
treatment [17, 18].
The study protocol was approved by the Local Ethics 
Committee, and the study was conducted in compliance with 
the Helsinki Declaration.
Patient groups
According to recent papers and guidelines, we set arbitrary 
cut-off values: for lactate at 2 mmol/L and for sTfR at 1.59 mg/L 
(95th percentile in healthy peers) [8, 15, 16, 19]. On this basis, 
patients were divided into three groups:
 — group 1: patients with both markers below the cut-off values;
 — group 2: individuals with separate elevation of either 
lactates or sTfR;
 — group 3: patients with both values above the predefined 
cut-off values.
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Statistical analysis
The end-point of the study was all-cause death at one-year 
follow-up. Continuous variables with a normal distribution 
were described using means ± standard deviation, variables 
with skewed distribution were described by medians with 
upper and lower quartiles, and categorical variables were 
provided as numbers and percentages. The variables with 
skewed distribution were log-transformed where appropriate. 
The comparison between groups with different sTfR and lactate 
profiles was made using the analysis of variance (Kruskal-Wallis 
test) and the c2 test where appropriate. The Cox proportional 
hazards model was used to calculate the hazard ratio (HR) with 
the corresponding 95% confidence interval (CI) for all-cause 
mortality. Afterwards, the HR was adjusted for systolic blood 
pressure, serum sodium, or creatinine (each adjustment was 
made separately due to a low number of events). Kaplan-Meier 
curves for cumulative survival were constructed. A value of 
p < 0.05 was considered statistically significant. Statistical 
analyses were performed using the STATISTICA 13 data analysis 
software system (StatSoft, Inc., Tulsa, OK, USA).
RESULTS
Characteristics
The study population consisted of 89 AHF patients at a mean 
age of 65 ± 13 years, including 64 (72%) men, with pre-
dominant ischaemic HF aetiology (47 cases, 53%). There were 
24 (27%) patients with de novo AHF, the remaining 65 pa-
tients had decompensation of chronic HF. The mean base 
characteristics on admission were as follows: ejection fraction 
(EF): 32% ± 13%, heart rate: 92 ± 26 bpm, systolic blood 
pressure: 135 ± 36 mmHg, creatinine: 1.3 ± 0.6 mg/dL, 
and haemoglobin: 13.3 ± 1.8 g/dL. The median (25th–75th 
quartiles) NT-proBNP and lactate levels on admission were: 
7550 (2928–8775) pg/mL and 2.0 (1.6–2.6) mmol/L, respec-
tively. The detailed characteristics of the study population are 
shown in Table 1.
The mean values of iron status markers were: serum 
iron: 61 (48–87) µg/dL, TSAT: 17.8% (13.9%–25%), ferritin: 
92.4 (62.5–153.2) µg/L, and sTfR: 1.9 (1.5–2.7) mg/L (Table 1).
Comparison of patients with different  
sTfR/lactate profiles
Only 17 (19%) patients had both lactate and sTfR levels below 
the cut-off values (group 1). In total, 38 (43%) individuals 
had separate elevation of either lactates (nine patients) or 
sTfR (29 patients) on admission (group 2). In the remaining 
34 (38%) patients, both markers were above the predefined 
cut-off values (group 3). There was no difference in basic 
clinical variables between patients with different lactate and 
sTfR profiles (Table 2). Patients in whom both biomarkers 
were elevated had higher values on liver function tests (AST: 
29 [26–40] IU/L and bilirubin: 1.1 [0.8–2.4] mg/dL) on admis-
sion compared to the other groups (p < 0.05). Apart from that, 
Table 1. Baseline characteristics of patients with acute heart 
failure
Parameter Population (n = 89)
Male sex 64 (72)
Age [years] 65 ± 13
Heart rate [bpm] 92 ± 26
SBP on admission [mmHg] 135 ± 36
Left ventricular ejection fraction [%] 32 ± 13




Valve disease 18 (20)
Comorbidities:
Previous MI 33 (37)
Hypertension 59 (66)
Atrial fibrillation 52 (58)
Diabetes mellitus 34 (38)
Liver function tests:
AST [IU/L] 26 [20–36]
ALT [IU/L] 26 [17–37]
Bilirubin [mg/dL] 1.1 [0.8–1.6]
Blood count:
Haemoglobin [g/dL] 13.3 ± 1.8
White blood cell count [G/L] 9 ± 3.8
Platelet count [G/L] 221 ± 99
Serum sodium [mmol/L] 138 ± 5
Creatinine [mg/dL] 1.3 ± 0.6
CRP [mg/L] 7.2 [3.0–19]
NT-proBNP [pg/mL] 7550 [2928–8775]
Troponin I [ng/mL] 0 [0–0.1]
Iron biomarkers:
Serum iron [µg/dL] 61 [48–87]
TIBC [µg/dL] 352 [305–389]
TSAT [%] 17.8 [13.9–25]
Ferritin [µg/L] 92.4 [62.5–153.2]
sTfR [mg/L] 1.9 [1.5–2.7]
Iron deficiency* 66 (74)
Hepcidin [ng/mL] 12.9 [3.1–34.2]
Peripheral blood gas test:
pH 7.4 ± 0.1
sO2 [%] 91 ± 9
pCO2 [mmHg] 39 ± 13
HCO3
– [mmol/L] 24 ± 4
Lactate [mmol/L] 2.0 [1.6–2.6]
In-hospital:
SBP at 48 h [mmHg] 115 ± 18
Creatinine at 48 h [mg/dL] 1.2 ± 0.6
Length of hospitalisation [days] 10 ± 8.9
Dyspnoea on admission (0–10 scale) 7.5 ± 1.9
Dyspnoea at 48 h (0–10 scale) 2.2 ± 2.4
Inotrope use 6 (7)
Dose of furosemide (IV) 0–4 h [mg] 95 ± 61
Dose of furosemide (IV) 24–48 h [mg] 44 ± 51
Data are shown as number (percentage), mean ± standard deviation 
or median [25th–75th quartiles]. ALT — alanine aminotransferase;  
AST — aspartate aminotransferase; CRP — C-reactive protein;  
HCO3
– — bicarbonate; MI — myocardial infarction; NT-proBNP —  
N-terminal pro–B-type natriuretic peptide; pCO2 — partial pressure of  
carbon dioxide; SBP — systolic blood pressure; sO2 — oxygen saturation; 
sTfR — soluble transferrin receptor; TIBC — total iron-binding capacity, 
TSAT — transferrin saturation
*Defined by serum ferritin and TSAT (serum ferritin < 100 µg/L,  
or serum ferritin 100–299 µg/L and TSAT < 20%)
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Table 2. Comparison of patients with different soluble transferrin receptor (sTfR) and lactate profiles
Parameter Group 1: patients 
with normal sTfR 
and lactate levels 
(n = 17)
Group 2: patients with 
abnormal level of 
either sTfR or lactate 
(n = 38)
Group 3: patients 
with abnormal 
levels of both sTfR 
and lactate (n = 34)
p
Male sex 10 (59) 29 (76) 25 (74) 0.39
Age [years] 64 ± 14 66 ± 13 65 ± 13 0.9
Heart rate [bpm] 85 ± 27 93 ± 27 94 ± 25 0.2
SBP on admission [mmHg] 140 ± 33 134 ± 32 134 ± 41 0.7
Left ventricular ejection fraction [%] 32 ± 13 32 ± 14 31 ± 12 0.7
Acute heart failure (de novo) 12 (71) 25 (66) 28 (82) 0.27
Heart failure aetiology:
Ischaemic 8 (47) 18 (47) 17 (50) 0.95
Hypertension 1 (6) 4 (11) 2 (6)
Valve disease 4 (24) 6 (16) 8 (24)
Comorbidities:
Previous MI 5 (29) 13 (34) 15 (44) 0.52
Hypertension 12 (71) 26 (68) 21 (62) 0.76
Atrial fibrillation 10 (59) 25 (66) 17 (50) 0.39
Diabetes mellitus 3 (18) 14 (37) 17 (50) 0.07
Liver function tests:
AST [IU/L] 22 [21–36] 23 [18–26]b 29 [26–40] 0.01
ALT [IU/L] 25 [17–36] 26 [16–35] 26 [19–42] 0.6
Bilirubin [mg/dL] 0.8 [0.6–1.1] 1.1 [0.8–1.6] 1.1 [0.8-2.4]ccc 0.01
Blood count:
Haemoglobin [g/dL] 13.1 ± 2 13.8 ± 1.7 13.3 ± 1.7 0.25
White blood cell count [G/L] 9.4 ± 3.2 8.3 ± 3.2 9.7 ± 4.4 0.4
Platelet count [G/L] 224 ± 74 228 ± 120 214 ± 86 0.81
Serum sodium [mmol/L] 138 ± 7 138 ± 3 138 ± 5 0.6
Creatinine [mg/dL] 1.1 ± 0.2 1.3 ± 0.6 1.4 ± 0.8 0.25
CRP [ml/L] 6.1 [2.1–14] 5.6 [3–14] 9.5 [4–20] 0.51
NT-proBNP [pg/mL] 4351 [2674–7910] 6037 [2502–9111] 6396 [3784–8287] 0.54
Troponin I [ng/mL] 0 [0–0.1] 0.1 [0–0.1] 0 [0–0.1] 0.29
Iron biomarkers:
Serum iron [µg/dL] 73 [54–96] 60 [47–74] 62 [47–90] 0.45
TIBC [µg/dL] 342 [287–380] 363.5 [319–397] 349 [298–387] 0.35
TSAT [%] 23.9 [14.7–30.0] 17.6 [12.9–20.7] 17.8 [15–26] 0.15
Ferritin [µg/L] 90.6 [71.1–198.2] 85.7 [65–149.7] 98 [59.9–152.2] 0.93
sTfR [mg/L] 1.4 [1.2–1.5]aa 1.9 [1.6–2.5]bbb 2.5 [1.8–3.7]ccc < 0.001
Iron deficiency* 11 (64) 30 (79) 25 (76) 0.5
Hepcidin [ng/mL] 26.4 [17–60] 7.9 [2.7–30] 7.2 [2.6–27]
Peripheral blood gas test:
pH 7.4 ± 0.1 7.4 ± 0.1 7.4 ± 0.1 0.32
sO2 [%] 91 ± 9 94 ± 4 89 ± 12 0.48
pCO2 [mmHg] 42 ± 18 39 ± 11 38 ± 11 0.59
HCO3
– [mmol/L] 26 ± 3 25 ± 4 23 ± 3c 0.01
Lactate [mmol/L] 1.6 [1.6–1.9] 1.6 [1.4–2.0]bbb 2.7 [2.3–3.3]ccc < 0.001
In-hospital:
SBP at 48 h [mmHg] 119 ± 4.5 114.5 ± 2.9 115 ± 3.2 0.74
Creatinine at 48 h [mg/dL] 0.99 ± 0.2 1.29 ± 0.1 1.22 ± 0.1 0.27
Length of Hospitalisation [days] 8.2 ± 5 8.9 ± 5 12.8 ± 12 0.1
Dyspnoea on admission (scale of 0–10) 7.0 ± 2.5 7.3 ± 1.8 8.0 ± 1.8 0.36
Dyspnoea at 48 h (0–10 scale) 2.9 ± 1.6 2.5 ± 1.9 3.1 ± 2.3 0.41
Inotrope use 0 (0) 1 (3) 5 (15)c 0.058
Dose of furosemide (IV) 0–24 h [mg] 91 ± 49 98 ± 66 94 ± 64 0.9
Dose of furosemide (IV) 24–48 h [mg] 29 ± 38 35 ± 51 62 ± 55 0.035
Data are shown as number (percentage), mean ± standard deviation or median [25th–75th quartiles]. Abbreviations — see Table 1
a/b/cp < 0.05; aa/bb/ccp < 0.01; aaa/bbb/cccp < 0.001; a — comparison between group 1 and 2; b — comparison between group 2 and 3;  
c — comparison between group 1 and 3
*Defined by serum ferritin and TSAT (serum ferritin < 100 µg/L, or serum ferritin 100–299 µg/L and TSAT < 20%)
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we found no difference between the three groups in most of 
the laboratory variables, such as blood count, Na+, creatinine, 
NT-proBNP, troponin, C-reactive protein, pH, and saturation 
(Table 2). Moreover, the comparison of iron status (assessed 
by serum iron, TIBC, ferritin, and TSAT) between the groups 
did not reveal any differences (Table 2).
Predictive value
During one-year follow-up 23 (26%) patients died. Univariate 
models confirmed that well-established risk factors, such as 
serum sodium (HR 0.9, 95% CI 0.8–0.9, p < 0.05), creati-
nine (HR 2.3, 95% CI 1.5–3.6, p < 0.05), and NT-proBNP(log) 
(HR 2.3, 95% CI 1.4–3.9, p < 0.05) had predictive values 
in our cohort. Moreover, separate elevation of either marker 
also had significant prognostic importance (HR 3.4, 95% CI 
1.3–8.7, p < 0.05 for lactate and HR 4.9, 95% CI 1.1–20.9, 
p < 0.05 for sTfR) (Table 3).
Patients with coexisting elevated levels of lactate and sTfR 
had a significantly higher mortality rate than groups 1 and 2: 
50% vs. 11.7% and 10.5%, respectively (log rank p < 0.001) 
(Fig. 1). Thus, group 3 had significantly higher mortality risk 
when compared to the rest of the population (HR 5.6, 95% CI 
2.2–14, p = 0.0003), which remained significant even after 
adjustments for each of the following: sodium, creatinine, 
NT-proBNP, or eGFR (Table 3).
DISCUSSION
To the best of our knowledge, this is the first report showing 
that patients with unmet iron cell requirements (defined as 
sTfR > 1.59 mg/L) who also demonstrate elevated lactate 
levels on admission have significantly higher mortality risk 
when compared to individuals without these pathologies. The 
detailed mechanisms of that phenomenon remain unknown; 
however, we may speculate that there should be a pathophysi-
Table 3. Predictors of one-year mortality: univariate and multivariate analyses
Variable HR (95% CI) p
Univariate analyses:
SBP (per 1 mmHg) 0.9 [0.9–1.0] 0.08
Serum sodium (per 1 mmol/L) 0.9 [0.8–0.9] < 0.0005
Creatinine (per 1 mg/dL) 2.3 [1.5–3.6] 0.0004
eGFR (per 1 mL/min) 0.9 [0.9–0.9] 0.001
Haemoglobin (per 1 g/dL) 0.8 [0.6–0.9] < 0.05
NT-proBNPlog (per pg/mL) 2.3 [1.4–3.9] 0.002
sTfR > 1.59 mg/L 4.9 [1.1–20.9] 0.03
Lactate > 2 mmol/L 3.4 [1.3–8.7] 0.009
sTfR > 1.59 mg/L and lactate > 1.59 mg/L 5.6 [2.2–14.3] 0.0003
Multivariate analyses:
sTfR > 1.59 mg/L and lactate > 1.59 mg/L (yes)* 5.4 [2.1–13.7] 0.0005
sTfR > 1.59 mg/L and lactate > 1.59 mg/L (yes)** 5.5 [2.1–14.0] 0.0005
sTfR > 1.59 mg/L and lactate > 1.59 mg/L (yes)*** 5.5 [2.2-14.2] 0.0003
sTfR > 1.59 mg/L and lactate > 1.59 mg/L (yes)**** 6.2 [2.4–16.4] 0.0002
*Adjusted for serum sodium; **Adjusted for creatinine; ***Adjusted for estimated glomerular filtration rate (eGFR); ****Adjusted for NT-proBNPlog
eGFR assessed by the Modification of Diet in Renal Disease (MDRD) formula: eGFR = 175 × serum Cr–1.154 × age–0.203 × 1.212 (if patient is black) 
× 0.742 (if female). Serum creatinine in mg/dL was used for this formula. Abbreviations — see Table 1
Figure 1. Kaplan-Meier curves. Probability of survival in 
patients with different lactate and soluble transferrin receptor 
(sTfR) profiles (n = 89); Group 1 — patients with both markers 
(lactate and sTfR) below cut-off values; Group 2 — patients 
with elevation of either lactate or sTfR levels; Group 3 — pa-
tients with both markers above the predefined cut-off values
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ological link between intracellular iron status, the ability to 
produce (and consume) energy, and mortality in AHF. The 
aforementioned mechanism is definitely complex and much 
more sophisticated than just “simple” iron deficiency-driven 
anaemia or hypoxia because we found no differences in 
haemoglobin values and oxygen saturation across the three 
groups. Moreover, we have recently reported that lactate is not 
correlated with respiratory disturbances in the broad spectrum 
of HF patients [20]. We believe that the coexistence of these 
two factors is not accidental and may actually identify patients 
with functional intracellular iron insufficiency that leads to 
energy debt with its clinical consequences.
The pathophysiology of lactate accumulation in AHF is 
definitely complex. As already mentioned, there are several 
mechanisms that may conspire in promotion of hyperlactatae-
mia in AHF [8, 21]. Recently, new insights into pathophysiology 
of hyperlactataemia have been revealed, which can change 
our understanding of this phenomenon [22]. Accumulation of 
lactate during stress may actually be a result of its aerobic (not 
anaerobic) production, which is controlled by the adrenergic 
system [22]. Hyperlactataemia may be an adaptation to stress 
related to increased energetic demand and sympathetic nerv-
ous system activation, which lead to accelerated glycolysis 
[22]. Lactate itself may be a source of energy for some cells, 
thus it may have protective capabilities [22–25]. In fact, our 
previous observations seem to confirm that assumption, as in 
HF patients; adrenergic drive (represented by heart rate), tissue 
hypoperfusion (expressed as systemic vascular resistance), and 
depressed lactate clearance (liver dysfunction) were strongly 
correlated with lactate [8, 20]. There was no evidence to link 
lactate with hypoxia and hypoxaemia in our HF population [20]. 
Moreover, there are grounds to believe that lactate may facilitate 
modification of protein expression that leads to more efficient 
energy consumption [22]. It is worth noting that, irrespective of 
its pathophysiological background, hyperlactataemia remains 
a marker of energetic stress.
The three groups were virtually the same in the context 
of well-established AHF prognostic factors, such as systolic 
blood pressure, serum sodium, creatinine, NT-proBNP, or 
troponin level on admission [26–28]. This observation may 
suggest that the prognostic importance of coexisting elevation 
of lactate and sTfR levels was irrespective of these vital vari-
ables. Multivariable analyses were not possible to perform due 
to the low number of events during follow-up, however, an 
adjustment for one of the following: natriuretic peptide, serum 
sodium, creatinine, or eGFR confirmed that assumption. It 
is also worth noting that almost three-fourths of all deaths 
(17 out of 23) occurred in patients with high levels of lactate 
and sTfR, which confirms their strong prognostic significance.
Moreover, the groups did not differ in markers commonly 
used for iron status assessment (apart from sTfR). This is con-
sistent with previous reports suggesting that the definition of 
iron deficiency is not universal and may need modification 
in some specific conditions [15].
Our study does not present the full picture of the inter-
relations between iron status, energy consumption, and out-
come in HF. However, we believe that we have revealed a hint 
of a pathophysiological link between them. We assume that 
during each episode of AHF a patient is exposed to energetic 
stress. It remains unknown whether the elevation of lactate is 
a result of the inability to physiologically adapt to the stress (i.e. 
due to iron deficiency) or whether the lactate level is rather 
a marker of the magnitude of the stress (because every patient 
may be exposed to different magnitudes of the stressor). Most 
likely it is a combined effect of these two phenomena.
Unexpectedly, we found that patients with elevated 
lactate and sTfR had some signs of worse clinical course of 
the disease (a trend towards longer hospital stay, higher furo-
semide and inotrope requirements), although this could not 
have been predicted using the baseline clinical and laboratory 
profiles. Furthermore, the poor response to therapy was not 
anticipated by the treating physicians because all groups re-
ceived the same doses of diuretic within the first 24 h (Table 2).
Recently, we reported that AHF patients with unmet cellular 
iron requirements (sTfR) accompanied by depleted iron stores 
(hepcidin) represent a group with very unfavourable prognosis 
(mortality rate reaching 40%) [16]. Moreover, we also demon-
strated that elevated level of lactate in AHF patients without clinical 
signs of hypoperfusion is related to end-organ damage and high 
one-year mortality [8]. Our present analysis shows a different 
perspective on lactate and iron status in AHF pathophysiology be-
cause we have tried to reveal a link between functional intracel-
lular iron insufficiency leading to energy debt and poor outcome.
There are several limitations to the presented analysis. The 
first and the most obvious one is a low number of examined 
patients and, therefore, a low number of events recorded during 
follow-up. Secondly, a serial assessment of lactate levels would 
probably be more adequate in identification of patients unable 
to cope with the stress related to AHF. Moreover, we have only 
provided data on lactate measured in capillary blood. Recently 
published studies showed a good correlation between lactate 
measured in capillary and arterial blood samples; however, one 
has to be cautious because the capillary blood may tend to reveal 
higher lactate values, especially in shock populations, which 
was not a case in our study [29–31]. In addition, the utility of 
hand-held devices for capillary lactate assessment in a population 
of patients after acute myocardial infarction has been shown [32]. 
Lastly, our hypothesis of energetic stress related to episodes of 
AHF needs to be further verified in future prospective studies.
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WHAT IS NEW?
We believe that there is a physiological link between intracellular iron status and efficiency of energy production/consump-
tion (assessed by lactate, a product of anaerobic cell metabolism), which may further impact the outcome of patients with 
acute heart failure (AHF). During each AHF episode patients are exposed to metabolic stress, and those unable to cope 
with the stress may have a worse outcome. We aimed to examine if elevated lactate levels (> 2 mmol/L) accompanied by 
unmet cellular iron requirements (defined as the elevation of soluble transferrin receptor > 1.59 mg/L) on admission identify 
patients with an unfavourable outcome. We have shown that coexistence of iron deficiency and elevated lactate is very 
common among patients with AHF, occurring in approximately 40% of cases. Moreover, for the first time, we have shown 
that a group of patients with hyperlactataemia and elevated soluble transferrin receptor on admission have significantly 
higher mortality risk when compared to individuals without those pathologies. It is possible that iron supplementation in 
AHF may promote more efficient energy production pathways, but this needs to be prospectively examined.
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